JGC
DSGN icon

J. Goldman & Co’s Design Therapeutics DSGN Stock Holding History

J. Goldman & Co’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Buy
+176,770
New +$2.2M 0.07% 302

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

J. Goldman & Co's DSGN Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Design Therapeutics (DSGN) in Q2 2026: 176,770 shares worth $2.56M. The stake represents 0.07% of the portfolio and ranks #302 among its holdings.

137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • J. Goldman & Co held 176,770 shares of Design Therapeutics worth $2.56M as of Q2 2026.
  • Design Therapeutics was a new J. Goldman & Co position in Q2 2026.
  • Design Therapeutics made up 0.07% of J. Goldman & Co's portfolio in Q2 2026, its #302 holding.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.